BRAF V600E, dabrafenib, Mekinist, melanoma, Novartis, Tafinlar, Trametinib
Dabrafenib in combination with trametinib is approved by FDA for unresectable or metastatic solid tumors with BRAF V600E mutation
July 2022: Dabrafenib (Tafinlar, Novartis) and trametinib (Mekinist, Novartis) received accelerated approval from the Food and Drug Administration for the treatment of adult and paediatric patients older than 6 years old with unre..
Lancet, Mekinist, Tamoxifen, Trametinib
New treatment identified for low grade and serous ovarian cancer
May 2022: Trametinib may become a new standard of care for recurring, low-grade serous ovarian cancer (Mekinist). According to study findings published in the February 2022 issue of The Lancet, trametinib beat both chemotherapy an..
Acalabrutunib, Avelumab, CART therapy, Dabrafanib, Kymriah, Latest drugs, Midostaurin, Niraparib, Pembrolizumab, Tecartus, Tisagenlecleucel, Trametinib, USFDA
Latest drugs in the treatment of cancer
July 2021: Check out the latest drugs in the treatment of cancer. Every year, after examining the trials and other important factors, the USFDA approves drugs, and thus cancer patients can now believe that a cure is very near. ..